TY  - CHAP
T1  - Medical treatment for urogenital tuberculosis (UGTB)
T2  - Urogenital Infections and Inflammations
AU  - Wejse, Christian
ED  - Naber, Kurt G.
AD  - Assoc. Prof.  Christian Wejse, Aarhus University, Aarhus University Hospital, Department of Infectious Diseases/Center for Global Health, Dept of Public Health, -, -, Dänemark, Phone: -, E-mail: wejse@dadlnet.dk
N2  - Urogenital tuberculosis (UGTB) should in general be treated as pulmonary TB with a four-drug regimen of Isoniazid, Rifampicin, Ethambutol and Pyrazinamide for a total of 6 months, Ethambutol and Pyrazinamide only the first two months. Some patients may need longer treatment (cavitary disease, kidney abscess/malfunction, HIV co-infection). Treatment of multi-drug resistant tuberculosis (MDR-TB) requires use of long-term intravenous treatment with aminoglycosides and other drugs with considerable toxicity for 18–24 months. Complications such as urinary tract obstruction may occur and should be treated with corticosteroids or surgery. 
PY  - 2018
DA  - 2018/08/09
DO  - 10.5680/lhuii000037
LA  - en
L1  - https://books.publisso.de/de/system/getFile/118
UR  - https://dx.doi.org/10.5680/lhuii000037
L2  - https://dx.doi.org/10.5680/lhuii000037
PB  - German Medical Science GMS Publishing House
CY  - Berlin
ER  -